Loading
A phase 3 trial of Vebreltinib in non-small-cell lung cancer, run by Beijing Pearl Biotechnology Limited Liability Company, now recruiting.
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive is a phase 3 interventional study registered as NCT06930794 by Beijing Pearl Biotechnology Limited Liability Company, with 300 participants planned, started 2025-07-07 and due to reach its primary completion in 2029-02. Interventions recorded: Vebreltinib combined with platinum-based doublet chemotherapy. and platinum-based doublet chemotherapy..
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.